ClinicalTrials.gg
RecruitingNCT07135310Updated Nov 16, 2026

STROKE 120 ACTION Trial

An interventional study of STROKE 120 multifaceted intervention campaign in Ischemic Stroke, sponsored by Shanghai Minhang Central Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Shanghai Minhang Central Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Nov 16, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,696,000
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 754 studies in Ischemic Stroke with a site in China — 381 open to participants now, 400 under way, 78 of them phase 3. Ischemic Stroke · China.

Planned enrollment
Largest of 566
1,696,000 · median 271
Started
2025
with 106 others
No phase
247 of 754
122 open now
Primary completion
2027-01
later than 182 of 399 live
Registered
587th of 754
by date

Among the 754 studies in Ischemic Stroke with a site in China, this one has the largest planned enrollment of the 566 interventional ones that give a count, is one of 107 that started in 2025, is one of 247 with no phase, reaches primary completion later than 182 of the 399 other live ones, and was the 587th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

381 of the 754 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:

376 more — sign in →

All 381 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 754 studies in Ischemic Stroke with a site in China, or all of them as a file.
02

Study summary

Stroke is the main cause of death and disability in China, but it is preventable and treatable. For the most common type, acute ischemic stroke (AIS), initiating reperfusion therapy with intravenous thrombolysis (IVT) with or without mechanical thrombectomy (MT) within several hours of the onset of symptoms can significantly improve the chances of surviving free of major disability, and earlier the intervention is given the better the outcome. Thus, whether patients can achieve timely arrived at hospital, ideally within the critical 4.5-hour golden window, is pivotal to achieving high rates of recanalization and optimal functional outcome. To this end, it is important to note that the overall pre-hospital delay for patients with AIS is currently 24 hours in China.

We plan to conduct STROKE 120 ACTION, a national cluster randomized controlled trial, to determine whether implementing a STROKE 120 multifaceted intervention campaign can reduce pre-hospital delay in AIS, increase the 4.5-hour hospital arrival rate, and improve survival, disability, and healthcare costs. The STROKE 120 ACTION trial will recruit 16 community units across 8 regions in China, with each region enrolling 2 community units with a residential population of at least 110,000 and comparable demographic characteristics. To avoid cross-contamination, the participating community clusters will maintain a physical distance of more than 20 kilometers. Within each region, the 2 community units will be randomly assigned at a 1:1 ratio to receive the intervention (12-month usual health policy plus STROKE 120 multifaceted intervention campaign; 3-month intensive period and 9-month maintenance period) or control (12-month usual health policy alone). The study outcomes and related data on incident AIS cases within each participating community unit will be collected after the implementation of STROKE 120 multifaceted intervention campaign (from month 1 to month 12 of multifaceted intervention campaign). The primary outcome is proportion of hospital arrival within 4.5 hours after symptom onset within participating community units. Secondary outcomes include time from onset to hospital admission, time from onset to action, use of 120 emergency ambulances, IVT, MT, total hospitalization costs, out-of-pocket costs, composite outcome of death or major disability (modified Rankin scale score [mRS] ≥3) at 3 months, ordinal 7-level mRS score at 3 months, all-cause mortality within 3 months. The sample size was calculated according to the following estimates: (1) a significance level of 0.05 for a 2-sided test; (2) statistical power of 85%; (3) 4.5-hour hospital arrival rate of 10% for AIS patients in control group; (4) 4.5-hour hospital arrival rate of 20% among AIS patients in intervention group; (5) intra-class correlation coefficient of 0.03; and (6) a 10% loss to follow-up. The estimated sample size is 3,312 incident AIS patients from 16 community units with an average cluster size of 207 patients per community unit. The annual incidence of AIS is 195 per 100,000 people, and the sample size of participants in each community unit will be 106,000. Thus, the total sample size of the present study will be 1,696,000 participants from 16 community units.

The STROKE 120 ACTION trial will address the critical issue of long pre-hospital delay in AIS in China, and provide profound implications for global stroke prevention and control strategies.

03

Conditions studied

  • Ischemic Stroke

Browse trials for

Keywords

  • Ischemic stroke
  • Pre-hospital delay
  • Cluster-randomized trial
04

Who can participate

The criteria were revised on the registry on Nov 16, 2026. See what changed

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

This trial will evaluate whether the STROKE 120 multifaceted intervention campaign can reduce the pre-hospital delay in AIS and increase the 4.5-hour arrival rate in 16 community units across 8 regions in China. We will select 2 community units from each region as the study sites and randomly divide the 2 community units within each region into the intervention group and the control group.

The selection criteria for community units are listed as follows:

  1. The 2 participating community units in each region should each have a permanent population over 110,000 (people aged 60 years and above accounting for at least 15%), have similar demographic characteristics (e.g., age, gender, and education level), and have comparable local health policies (e.g., medical insurance policies, emergency system framework, stroke emergency map release, and stroke center quality control), economic levels, and public ability to recognize AIS.
  2. The participating hospitals in each community unit serve >90% of AIS patients within the community unit, have a well-established stroke center, and have comparable standardized treatment capabilities for AIS (including 4.5-hour hospital arrival rate of AIS, rate of using 120 emergency ambulances after AIS, and rate of IVT after AIS).
  3. The participating communities are capable of implementing STROKE 120 multifaceted intervention campaign within its community unit.
  4. To avoid cross-contamination, the physical distance between any two community units exceeds 20 kilometers.

The inclusion criteria for registering cases are listed as follows:

  1. Clinical diagnosis as acute ischemic stroke (the diagnosis following the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018).
  2. Time from onset to hospital is within 7 days.
  3. Residing within the participating community units.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,696,000 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Usual health policy plus STROKE 120 multifaceted intervention campaign

    Behavioral: STROKE 120 multifaceted intervention campaign

  • No intervention
    Control group

    Usual health policy alone

Interventions

  • BehavioralSTROKE 120 multifaceted intervention campaign

    Based on the existing usual health policy, the intervention group will implement a STROKE 120 multifaceted intervention campaign in the intervention community units for a continuous period of 12 months (3-month intensive period and 9-month maintenance period). The detailed implementation plan for the STROKE 120 multifaceted intervention campaign in the intervention group is as follows: 1. Training medical workers in stroke center; 2. Training emergency center staff and primary care physicians; 3. Conducting public education;

06

What researchers measure

Primary outcomes

  1. Arriving hospital within 4.5 hours after symptom onset among incident acute ischemic stroke cases within participating community units

    Proportion of arriving hospital within 4.5 hours after symptom onset among incident acute ischemic stroke cases within participating community units

    Time frame: From month 1 to month 12 of multifaceted intervention campaign

Secondary outcomes

  1. Time from onset to hospital admission after acute ischemic stroke

    Time frame: From month 1 to month 12 of multifaceted intervention campaign

  2. Time from onset to action after acute ischemic stroke

    Time frame: From month 1 to month 12 of multifaceted intervention campaign

  3. Use of 120 emergency ambulances after acute ischemic stroke

    Proportion of using 120 emergency ambulances after acute ischemic stroke

    Time frame: From month 1 to month 12 of multifaceted intervention campaign

  4. Intravenous thrombolysis after acute ischemic stroke

    Proportion of intravenous thrombolysis after acute ischemic stroke

    Time frame: From month 1 to month 12 of multifaceted intervention campaign

  5. Mechanical thrombectomy after acute ischemic stroke

    Proportion of mechanical thrombectomy after acute ischemic stroke

    Time frame: From month 1 to month 12 of multifaceted intervention campaign

  6. Total hospitalization costs

    Time frame: At Hospital Discharge after ischemic stroke onset (ischemic stroke patients occurring from month 1 to month 12 of multifaceted intervention campaign)

  7. Out-of-pocket hospitalization costs

    Time frame: At Hospital Discharge after ischemic stroke onset (ischemic stroke patients occurring from month 1 to month 12 of multifaceted intervention campaign)

  8. Composite outcome of death or major disability at 3 months after acute ischemic stroke

    The composite outcome of death or major disability was defined as a score of 3 to 6 on the modified Rankin Scale at 3 months after ischemic stroke. Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death.

    Time frame: Three months after ischemic stroke (ischemic stroke patients occurring from month 1 to month 12 of multifaceted intervention campaign)

  9. Ordinal 7-level modified Rankin Scale score at 3 months after acute ischemic stroke

    Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death.

    Time frame: Three months after ischemic stroke (ischemic stroke patients occurring from month 1 to month 12 of multifaceted intervention campaign)

  10. All-cause mortality within 3 months after acute ischemic stroke

    Time frame: Three months after ischemic stroke (ischemic stroke patients occurring from month 1 to month 12 of multifaceted intervention campaign)

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jan 2027, 13 months after the start.

Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 13 months is below that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Nov 2026 → Jan 2027 and completion Feb 2027 → Apr 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2025
First posted
Aug 22, 2025
StartActual
Dec 1, 2025
Primary completionEst.
Jan 24, 2027was Nov 2026
CompletionEst.
Apr 30, 2027was Feb 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 30, 2026→Jan 24, 2027
Nov 16, 2026
Study completion
Feb 28, 2027→Apr 30, 2027
Nov 16, 2026
Eligibility
1 criterion edited, 5 added
What changed in the criteria
  • EditedThis trial will evaluate whether the STROKE 120 multifaceted intervention campaign can reduce the pre-hospital delay in AIS and increase the 4.5-hour arrival rate in 16 community units across 8 regions in China. We will select 2 community units from each region as the study sites and randomly divide the 2 community units within each region into the intervention group and the control group. The selection criteria for community units are listed as follows:
  • AddedThe selection criteria for community units are listed as follows:
  • AddedThe inclusion criteria for registering cases are listed as follows:
  • AddedClinical diagnosis as acute ischemic stroke (the diagnosis following the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018).
  • AddedTime from onset to hospital is within 7 days.
  • AddedResiding within the participating community units.
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Primary completion Nov 30, 2026→Jan 24, 2027
    Study completion Feb 28, 2027→Apr 30, 2027
    Eligibility 1 criterion edited, 5 added
    What changed in the criteria
    • EditedThis trial will evaluate whether the STROKE 120 multifaceted intervention campaign can reduce the pre-hospital delay in AIS and increase the 4.5-hour arrival rate in 16 community units across 8 regions in China. We will select 2 community units from each region as the study sites and randomly divide the 2 community units within each region into the intervention group and the control group. The selection criteria for community units are listed as follows:
    • AddedThe selection criteria for community units are listed as follows:
    • AddedThe inclusion criteria for registering cases are listed as follows:
    • AddedClinical diagnosis as acute ischemic stroke (the diagnosis following the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018).
    • AddedTime from onset to hospital is within 7 days.
    • AddedResiding within the participating community units.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07135310
Lead sponsor
Shanghai Minhang Central Hospital
Responsible party
Jing Zhao (Chief of the Department of Neurology, Shanghai Minhang Central Hospital) — Principal investigator
First posted
Aug 22, 2025
Start date
Dec 1, 2025
Primary completion
Jan 24, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Nov 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion